Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $56.4 million.

  • Krystal Biotech's Operating Expenses fell 805.46% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 44.76%. This contributed to the annual value of $224.8 million for FY2024, which is 4013.94% up from last year.
  • Latest data reveals that Krystal Biotech reported Operating Expenses of $56.4 million as of Q3 2025, which was down 805.46% from $56.7 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Operating Expenses ranged from a high of $61.7 million in Q2 2024 and a low of $14.4 million during Q1 2021
  • Over the past 5 years, Krystal Biotech's median Operating Expenses value was $39.0 million (recorded in 2023), while the average stood at $40.2 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 24990.59% in 2022, then tumbled by 807.38% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Operating Expenses stood at $21.9 million in 2021, then skyrocketed by 58.95% to $34.8 million in 2022, then increased by 12.18% to $39.0 million in 2023, then rose by 27.72% to $49.8 million in 2024, then increased by 13.27% to $56.4 million in 2025.
  • Its Operating Expenses stands at $56.4 million for Q3 2025, versus $56.7 million for Q2 2025 and $52.0 million for Q1 2025.